Lysogene Announces Its Corporate Agenda For 2020

Nachrichtenquelle: Business Wire (engl.)
24.01.2020, 07:00  |  136   |   |   

Regulatory News:

Lysogene (Paris:LYS) (FR0013233475 – LYS) today announced its corporate agenda* for 2020:

17 February 2020:

Sales and cash position at the end of 2019

20 March 2020:

2019 annual results

22 April 2020:

First quarter 2020 sales and cash position

June 2020 (day to be confirmed later):

General shareholders’ meeting

24 July 2020:

Sales and cash position for the first half 2020

25 September 2020:

First half 2020 results

19 November 2020:

First nine months 2020 sales and cash position

* This financial calendar is for indicative purposes only and the Group could change its publication dates should it deem it necessary

The company also confirms that it expects to communicate in the first half of 2020 the following elements:

  • Completion of enrollment of the 20 patients in the phase II/III clinical trial (AAVance) evaluating the gene therapy LYS-SAF302 for the treatment of MPS IIIA (Sanfilippo syndrome type A)
  • IND (Investigational New Drug) clearance, prerequisite for starting the first-in-human clinical trial of LYS-GM101 in GM1 gangliosidosis

About Lysogene
Lysogene is a gene therapy company focused on the treatment of orphan diseases of the central nervous system (CNS). The company has built a unique capability to enable a safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A pivotal clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing and a phase 1-2 clinical trial in GM1 Gangliosidosis is in preparation. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene is also collaborating with an academic partner to define the strategy of development for the treatment of Fragile X syndrome, a genetic disease related to autism.

Seite 1 von 3
Lysogene and/or registered shares Aktie jetzt für 4€ handeln - auf

Diesen Artikel teilen

Diskussion: LYS.PA (Mkap €22 M) (Cash €33 M) Orphan Disease P3 partner Sarepta (SRPT)
Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Meistgelesene Nachrichten des Autors